A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Change in pigmented villonodular synovitis (PVNS) tumor size
A phase II randomized, double-blind, placebo controlled study to assess safety, tolerability and effect on tumor size of MCS110 in patients with pigmented villonodular synovitis (PVNS)
week 4
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CMCS110X2201
NCT01643850
April 2012
June 2013
Name | Location |
---|---|
Novartis Investigative Site | Chicago, Illinois 60612 |
Novartis Investigative Site | Sacramento, California 95817 |
Novartis Investigative Site | Miami, Florida 33176-2197 |
Novartis Investigative Site | Minneapolis, Minnesota 55455 |
Novartis Investigative Site | Washington, District of Columbia 20007-2197 |